5-Oxoproline Prevents Doxorubicin Heart Damage While Fighting Cancer

This groundbreaking study reveals that 5-oxoproline, a naturally occurring metabolite, offers a dual therapeutic approach for cancer patients receiving doxorubicin chemotherapy—protecting the heart while enhancing cancer treatment. This addresses a critical clinical need, as doxorubicin-induced cardiotoxicity limits the use of this highly effective chemotherapy drug.

Researchers used comprehensive metabolomic and transcriptomic analysis of heart tissue from mice with early doxorubicin-induced cardiotoxicity. They identified glutathione metabolism as the most disrupted pathway and found that 5-oxoproline levels were significantly decreased in both mouse and human samples. The team then tested whether supplementing with 5-oxoproline could restore heart function and affect tumor growth.

The results were remarkable: 5-oxoproline supplementation not only prevented doxorubicin-induced cardiac dysfunction but also enhanced the drug's antitumor effects. In mouse models, the metabolite restored normal heart function parameters and significantly reduced tumor growth compared to doxorubicin alone. The protective effects worked through two distinct mechanisms—restoring glutathione synthesis in heart cells via the enzyme OPLAH, while simultaneously inhibiting cancer cell proliferation by downregulating the enzyme GGCT.

The clinical implications are substantial. Current cardioprotective agents like dexrazoxane carry risks of secondary cancers, making this dual-action approach particularly valuable. The study also suggests 5-oxoproline could serve as an early biomarker for detecting cardiotoxicity before traditional measures show damage.

While promising, this research was conducted primarily in mouse models, and human clinical trials will be essential to confirm safety and efficacy. The optimal dosing, timing, and patient selection criteria also require further investigation before clinical application.